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Figure 1. Percent of control levels of 6 angiogenic factors at onset aGVHD in
CTN 0302 and 0802. Data presented are median  SEM.
Figure 2. Kaplan Meier estimate of OS based upon day 28 FS level.
Figure 1. Detection of in vitro activated alloreactive CD4+ T cells
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78 S57aGVHD enrolled in Blood and Marrow Transplant Clinical
Trials Network (BMT CTN) trials 0302 (N¼105, serum) and
0802 (N¼158, plasma). Samples were analyzed at aGVHD
onset and day 28 post-aGVHD treatment and compared to
control samples obtained at day +100 from University of
Minnesota allogeneic hematopoietic cell transplant (HCT)
recipients without aGVHD (N¼53, serum).
Results: In the pilot study, signiﬁcant differences in the levels
of FS, EGF, VEGF-A, PlGF, Ang2, and sEng were found when
comparing patients with aGVHD, allogeneic HCT recipients
without aGVHD, and HD in the pilot study. In the CTN vali-
dation cohorts (Figure 1), VEGF-A and EGF were signiﬁcantly
lower in patients with aGVHD compared to HCT controls. FS,
sEng, and PlGF were all signiﬁcantly elevated in patients
with aGVHD compared to controls. In multivariate analyses
of 6-month survival including age, stage, and day 28
response in the validation cohorts, the day 28 FS level was
an independent prognostic factor for survival in both CTN
0302 (HR 9.3, 95% CI 1.3e59.1, p¼0.002) and 0802 (HR 2.8,
95% CI 1.04e6.9, p¼0.04), with outcomes signiﬁcantly
worse when day 28 FS > 2000 pg/mL (Figure 2).Conclusions: Three circulating AFs are elevated in patients
with aGVHD: FS, sEng and PlGF. The level of FS at day 28 post
aGVHD was an independent prognostic factor for survival in
both CTN 0302 and 0802. Although FS is important for
regeneration after injury, excess FS may reﬂect more
extensive tissue, especially endothelial, damage or loss,
leading to higher mortality. Studies aimed at identifying the
source and mechanism of FS in aGVHD are ongoing. Our
results contribute to the growing body of knowledge
supporting the endothelium as a relevant target of aGVHD in
need of dedicated protection or therapy.41
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Using ﬂow cytometric techniques to directly analyze the
developing reactivity of T cells isolated from the recipient
after double cord blood transplant (dCBT) against cells
(B-LCL) derived from each donor, we previously reported
that naive CD8+ T cells in the engrafting unit are activated in
vivo by antigens expressed by non-engrafting unit, which
expand and differentiate into IFN-g secreting CD8+ effector T
cells. Surprisingly, our initial studies did not identify IFN-g
secreting alloreactive CD4+ T cells, despite the majority of CB
units being mismatched at one or more class II alleles
(Gutman et al. Blood 2010). However, these studies did
not exclude the possibility that CD4+ T cells, especially the
IFN-g- Th2 and Th17 cells, may be involved in the GvG
interactions of dCBT. Herein, we now demonstrate the
presence of alloreactive CD4+ T cells in dCBT recipients and
investigate their role in the GvG interaction. Included are 13
patients who underwent a myeloablative dCBT on an IRB
approved protocol between Feb 2013 and June 2014.
Post-transplant peripheral blood collection, donor B-LCL
generation, and in vitro MLR with intracellular cytokine
staining were performed as previously described (Gutman et
al. Blood 2010) with small revision. Our current experimental
approach includes the detection of surface marker CD137
Figure 2. Diagram of potention function of alloreactive CD4+ T ceIIs in dCBT
patients.
Figure 1. IL-22 induces epithelial regeneration ex vivo.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S58(4-1BB), a member of the tumor necrosis factor receptor
(TNFR)-family, as a means to identify a more encompassing
compartment of alloreactive T cells in addition to IFN-g
secretion. Consistent with our previous report, no signiﬁcant
CD4+ IFN-g secreting population was detected in the PBMCs
obtained from day 14 post-CBT patient blood after
stimulation with LCLs from the non-engrafting unit (Fig 1).
However, the frequency of CD4+ cells that express CD137
(median, 8.86%; range, 1.39-16.7%) was signiﬁcantly higher
than the frequency of IFN-g secreting cells (median, 2%;
range, 0.2-4.39%) when stimulated with LCLs from the
non-engrafting unit (p<0.0001). Moreover, the CD137
expressing CD4+ T cell population was speciﬁc for allogeneic
stimulation with signiﬁcantly higher CD137 expression
frequency when stimulated with LCLs from the non-
engrafting unit as compared to stimulation with LCLs from
the engrafting unit (p<0.0001, Fig 1). In summary, this study
provides the ﬁrst clear evidence that a distinct population of
CD137+IFN-g- CD4+ alloreactive T cells is present in the
peripheral blood of patients undergoing dCBT and are
involved in the GvG effects observed after dCBT. Functional
deﬁnition of this distinct population (Th2 or Th17) might
disclose an important role of GvG interactions in the
regulation of GVHD, the prevention of graft rejection, and the
maintenance of GVL effects as hypothesized by Fig 2.42
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Little is known about regulation of the intestinal stem cell
(ISC) compartment in gut GVHD. We have found that
Interleukin-22 (IL-22) is important for ISC recovery afterBMT. However, the mechanism and speciﬁc epithelial targets
of IL-22 are poorly understood.
Using clinically modeled LP into C57BL/6 (B6) minor anti-
gen-mismatched BMT (H-2b into H-2b), we found that daily
treatment with recombinant murine IL-22 (4ug IP starting D7
post-BMT) led to reduced GVHD pathology in small intestine
(SI) and large intestine (LI) three weeks after transplant
(p<0.001) without altering GVL or alloreactivity. Mice treated
with IL-22 (no pharmacologic immunosuppression) main-
tainedmore Lgr5+ ISCs and demonstrated signiﬁcantly greater
ISC proliferation (p<0.01). Although IL-22 is thought to
regulate Paneth cells (PCs), and PCs make up the SI stem cell
niche, IL-22-mediated protection of ISCs was not due to niche
augmentation, as PC numbers, PC-derived growth factors
(EGF, Wnt3), and stroma-derived growth factors (R-spondin
3) were all unchanged after IL-22 administration. However,
antimicrobial proteins Reg3b and Reg3g were both upregu-
lated in IL-22-treatedmice (p<0.01), suggesting enhanced gut
barrier function.
To evaluate direct effects on epithelial regeneration, we
performed intestinal organoid cultures in the presence of
IL-22. Organoids generated from wild-type B6 crypts
demonstrated substantially increased size after seven days of
culture with IL-22 (SI p<0.001, Fig. 1; LI p<0.05).
Co-culturing crypts with innate lymphoid cells, potent
producers of IL-22 in vivo, also led to increased organoid size.
IL-22 signiﬁcantly increased organoid EdU incorporation and
new crypt budding, and serial passaging with IL-22 greatly
increased organoid expansion, suggesting that IL-22 could
augment ISC regeneration. IL-22 receptor staining further
indicated a direct effect of IL-22 on ISCs rather than the stem
cell niche, as PCs were found to express very little IL-22
receptor (Fig. 2). Indeed, IL-22 led to expansion of the Lgr5+
ISC pool within SI organoids (Fig. 2), activated STAT3
phosphorylation in Lgr5+ cells, and increased size and
budding of organoids cultured from puriﬁed SI ISCs (p<0.05).
To investigate potential for clinical translation, we next
tested a recombinant human IL-22 dimer/Fc fusion molecule
(F-652, Generon Corp., Shanghai). F-652 signiﬁcantly
increased the size of SI and LI organoids (p<.05). Using the LP
into B6 BMT model described above, we also found that
treatment with F-652 (100 mg/kg subQ every other day
starting D7 post-BMT) signiﬁcantly improved both systemic
GVHD scoring and survival (Fig. 3).
In summary, we found that IL-22 can bridge immune
function and tissue regeneration by acting directly on
epithelial stem cells. IL-22 therapy may represent a
novel approach to promote intestinal recovery in GVHD
patients without increasing post-transplant immunode-
ﬁciency.
